Aakaar Medical Technologies Ltd
Aakaar Medical Technologies Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Top 7 Personal Products companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Aakaar Medical Technologies Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from operations in H1 FY27: INR 43.72 Cr, up 72.6% YoY from INR 25.32 Cr in H1 FY26 (Page 12, 11, 4) - EBITDA in H1 FY27: INR 5.43 Cr vs loss of INR 0.23 Cr in H1 FY26 (Page 12, 11) - PAT in H1 FY27: INR 3.54 Cr vs loss of INR 0.78 Cr in H1 FY26 (Page 12, 11) - Imported/Third Party Brands sales revenue: INR 28.7 Cr in H1 FY27 vs INR 44.5 Cr in FY26 full year (Page 32) - Aakaar own brand sales revenue: INR 14.9 Cr in H1 FY27 vs INR 22.4 Cr in FY26 full year (Page 31) - Revenue growth across segments noted (FY23 to FY26): significant expansions e.g. H1FY27 EBITDA: INR 5.43 Cr vs INR (0.23) Cr in H1FY26, showing a significant positive turnaround.
From Aakaar Medical Technologies Ltd's Q2 FY27 earnings-call transcript · updated 30 Oct 2026.
Revenue & Sales Performance
- Revenue from operations in H1 FY27: INR 43.72 Cr, up 72.6% YoY from INR 25.32 Cr in H1 FY26 (Page 12, 11, 4)
- EBITDA in H1 FY27: INR 5.43 Cr vs loss of INR 0.23 Cr in H1 FY26 (Page 12, 11)
- PAT in H1 FY27: INR 3.54 Cr vs loss of INR 0.78 Cr in H1 FY26 (Page 12, 11)
- Imported/Third Party Brands sales revenue: INR 28.7 Cr in H1 FY27 vs INR 44.5 Cr in FY26 full year (Page 32)
- Aakaar own brand sales revenue: INR 14.9 Cr in H1 FY27 vs INR 22.4 Cr in FY26 full year (Page 31)
- Revenue growth across segments noted (FY23 to FY26): significant expansions e.g. Injectable & Contouring 1 → 11 Cr, Homecare 5 → 11 Cr (Page 30)
- Explicit Outlook:
- H2 FY27 focus on business growth via increased brand and doctor productivity (Page 10)
- Shift payment responsibilities to distributors to reduce debtor days (<130 days) (Page 10)
2 more points from Aakaar Medical Technologies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Aakaar Medical Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Xelix FUE HT device manufacturing and R&D facilities investment mentioned; test license applied (Page 7).
- "DODO model" described as zero capex per clinic for partner clinics, indicating asset-light expansion without infrastructure burden (Page 23).
- Migration to Novacare and appointment of 40 distributors to improve operations and delivery (Page 10).
Top-ranked in Personal Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aakaar Medical Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Continue your research
What Aakaar Medical's management said in earlier quarters
Others in Personal Products this season
- Godrej Consumer Products Ltd (Q2 FY27)
Consolidated net sales for Q2 FY2027: ₹4,396 crore, up 19% year-on-year; constant currency growth 15% (Page 8) . Key investor presentation takeaways from Godrej
- Colgate-Palmolive (India) Ltd (Q2 FY27)
1,692 crore, up 12.2% year-on-year from Rs. Key results statement takeaways from Colgate-Palmolive (India) Ltd's Q2 FY27 results statement — and how it ranks ag
- Bajaj Consumer (Q2 FY27)
. Key concall takeaways from Bajaj Consumer's Q2 FY27 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Personal Products
on management's own guidance
- Strong growth2
- Strong growth1
- Honasa Consumer LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aakaar Medical Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aakaar Medical Technologies Ltd Q2 FY27 results?
Revenue from operations in H1 FY27: INR 43.72 Cr, up 72.6% YoY from INR 25.32 Cr in H1 FY26 (Page 12, 11, 4) - EBITDA in H1 FY27: INR 5.43 Cr vs loss of INR 0.23 Cr in H1 FY26 (Page 12, 11) - PAT in H1 FY27: INR 3.54 Cr vs loss of INR 0.78 Cr in H1 FY26 (Page 12, 11) - Imported/Third Party Brands sales revenue: INR 28.7 Cr in H1 FY27 vs INR 44.5 Cr in FY26 full year (Page 32) - Aakaar own brand sales revenue: INR 14.9 Cr in H1 FY27 vs INR 22.4 Cr in FY26 full year (Page 31) - Revenue growth across segments noted (FY23 to FY26): significant expansions e.g. H1FY27 EBITDA: INR 5.43 Cr vs INR (0.23) Cr in H1FY26, showing a significant positive turnaround.
What is Aakaar Medical Technologies Ltd share price analysis?
Aakaar Medical Technologies Ltd currently shows a neutral. The stock trades at a P/E of 15.2 with a market cap of ₹101 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aakaar Medical Technologies Ltd planning capital expenditure?
Xelix FUE HT device manufacturing and R&D facilities investment mentioned; test license applied (Page 7).
Keep Aakaar Medical Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.